Key Takeaways:
UroGen Pharma Ltd. on Tuesday reported first-quarter revenue of $50.9 million, driven by a 109% sequential surge in sales for its bladder cancer treatment, Zusduri.
The company's revenue for Zusduri reached $29.2 million, benefiting from a permanent J-code for insurance reimbursement that became effective Jan. 1. Sales of its other commercial drug, Jelmyto, rose 7% year-over-year to $21.7 million. The company did not disclose earnings per share data or provide consensus estimates.
The strong commercial uptake of Zusduri is a critical validation of UroGen's focus on urological treatments. Investors will be closely watching for the six-month durability data for the company's next-generation pipeline candidate, UGN-103, expected in mid-2026, ahead of a planned regulatory submission in the second half of the year.
The significant revenue growth from Zusduri follows the establishment of a permanent J-code, which simplifies the billing and reimbursement process for providers and is expected to broaden patient access. UroGen has indicated this has been a key factor in the drug's adoption.
To further highlight the real-world efficacy of the treatment, UroGen plans to host a Key Opinion Leader panel at the American Urological Association annual meeting on May 17.
The performance of Zusduri is central to UroGen's growth strategy as it continues to advance its pipeline. The upcoming data release and subsequent NDA submission for UGN-103 represent the next major catalysts for the company.
This article is for informational purposes only and does not constitute investment advice.
